PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events

@article{Agell2011PI3KSP,
  title={PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events},
  author={Laia Agell and Silvia Hernández and Marta Salido and Silvia de Muga and Nuria Juanpere and Montserrat Arum{\'i}-Ur{\'i}a and Silvia Men{\'e}ndez and Marta Lorenzo and Jos{\'e} Antonio Lorente and Sergi Serrano and Josep Lloreta},
  journal={Modern Pathology},
  year={2011},
  volume={24},
  pages={443-452}
}
The phosphatidylinositol 3-kinase (PI3K)–AKT and RAS–MAPK pathways are deregulated in a wide range of human cancers by gain or loss of function in several of their components. Our purpose has been to identify genetic alterations in members of these pathways in prostate cancer. A total of 102 prostate tumors, 79 from prostate cancer alone (group G1) and 23 from bladder and prostate cancer patients (G2), are the subject of this study. In 20 of these 23, the bladder tumors were also analyzed… 
Analysis of the PI3K-AKT-mTOR pathway in penile cancer: evaluation of a therapeutically targetable pathway
TLDR
The PI3K-AKT-mTOR pathway is not a key driver in PSCC carcinogenesis and the therapeutic targeting of this pathway is unlikely to produce significant clinical benefit.
PI3K regulatory subunit p85alpha plays a tumor suppressive role in the transformation of mammary epithelial cells
TLDR
In this dissertation, in vitro and in vivo approaches are used to examine the role of p85g as a tumor suppressor in the transformation of mammary epithelial cells and genetic ablation of Pik3r1 accelerates mammary tumor development.
Frequent copy number variations of PI3K/AKT pathway and aberrant protein expressions of PI3K subunits are associated with inferior survival in diffuse large B cell lymphoma
TLDR
Frequent CNVs of PIK3CA is highly associated with aberrant p110α protein expression and subsequent activation of PI3K/AKT pathway, and aberrant protein expression of p110 isoforms are of great important value for predicting inferior prognosis in DLBCL.
From genomics to functions: preclinical mouse models for understanding oncogenic pathways in prostate cancer.
TLDR
The power of genetically engineered mouse models (GEMMs) in translating genomic discoveries into understanding of the functions of these oncogenic events in vivo are highlighted.
Identification of frequent BRAF copy number gain and alterations of RAF genes in chinese prostate cancer
TLDR
The finding suggests that the activation of the RAS/RAF/MEK/ERK pathway may be frequent in Chinese prostate cancer, with RAF gene copy number gain potentially being the main contributor.
Eupafolin suppresses prostate cancer by targeting phosphatidylinositol 3‐kinase‐mediated Akt signaling
TLDR
Results suggested that eupafolin exerts antitumor effects by targeting PI3‐K, a natural compound found in common sage, inhibited proliferation of prostate cancer cells.
KRAS, BRAF, PIK3CA mutation frequency of radical prostatectomy samples and review of the literature
TLDR
KRAS mutation frequency is similar to those in Asian populations and BRAF and PIK3CA mutation frequencies have been reported in the literature in the range of 0–15% and 0–10.4%, respectively, consistent with the study findings.
...
...

References

SHOWING 1-10 OF 40 REFERENCES
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.
TLDR
Mutation of PIK3CA is frequent, occurs early in carcinoma development, and has prognostic and therapeutic implications and the association between ERBB2 overexpression and Pik3CA mutation implies that more than one input activating the PI3K/AKT pathway may be required to overcome intact PTEN.
Spectrum of Phosphatidylinositol 3-Kinase Pathway Gene Alterations in Bladder Cancer
TLDR
The lack of redundancy of alterations suggests that single-agent PI3K-targeted therapy may not be successful in these cancers, and a well-characterized series of cell lines are provided for use in preclinical studies of targeted agents.
PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas
TLDR
The first report of PIK3CA mutation in pancreatic cancer appears to be the first oncogene to be mutated in IPMN/IPMC but not in conventional ductal adenocarcinoma of the pancreas.
Genetic alterations in the PI3K pathway in prostate cancer.
TLDR
The results suggest that genetic alterations in the PI3K pathway are common in prostate cancer, and occur mainly through PIK3CA amplification and PTEN hemizygous or homozygous deletion.
Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population.
TLDR
A higher incidence of PIK3CA alterations and the possible synergistic effect of Pik3 CA alterations and BRAF mutations suggest their major role in Middle Eastern PTC tumorigenesis and argue for therapeutic targeting of PI3K/AKT and MAPK pathways.
Oncogenic PI3K and its role in cancer
TLDR
Both mutational and functional analyses have shown that PIK3CA is an oncogene that plays an important role in tumor progression, and gaining further insights into Pik3CA oncogenic mechanisms may produce new biomarkers and help the development of targeted therapeutics.
PIK3CA mutations in nasopharyngeal carcinoma
Dear Sir, By molecular cytogenetic studies, we have previously identified high frequency of copy number gain or amplification on chromosomes 3q (70%) in nasopharyngeal carcinoma (NPC), a prevalence
BRAF and KRAS mutations in prostatic adenocarcinoma
TLDR
The results obtained show that BRAF mutations are as uncommon as KRAS mutations in prostate adenocarcinoma, and although BRAF and KRAS are members of the same RAS/ERK signaling pathway, prostate adeccarcinomas with a BRAF mutation showed clinicopathologic features that differed from those of prostateAdenocARCinoma with a KRAS mutation.
Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer.
TLDR
The activation state of the cell survival protein Akt can be analyzed in human prostate cancer by immunohistochemical staining of paraffin-embedded tissue with a phospho-specific Akt (Ser473) antibody.
Cancer genetics of sporadic colorectal cancer: BRAF and PI3KCA mutations, their impact on signaling and novel targeted therapies.
TLDR
Identification of novel mutations as well as differential gene expression analyzed by microarray reveal potential targets for combined therapeutic protocols which will result in personalized treatments in the near future.
...
...